Table 1.
Baseline characteristics and outcomes by 24-months on ART Stratified by Age for patients at the Themba Lethu Clinic in Johannesburg, South Africa (n=9139)
| Age Group (years) | ||||||
|---|---|---|---|---|---|---|
| Characteristics | 18-29.9 | 30-39.9 | 40-49.9 | 50-59.9 | ≥60 | |
| Sex, n (%) | Female | 1340 (77.1) | 2586 (60.1) | 1289 (56.8) | 385 (53.4) | 47 (42.7) |
| Male | 398 (22.9) | 1716 (39.9) | 979 (43.2) | 336 (46.6) | 63 (57.3) | |
| Employed, n (%) | Yes | 562 (32.3) | 1922 (44.7) | 1107 (48.8) | 310 (43.0) | 41 (37.3) |
| No | 1176 (67.7) | 2380 (55.3) | 1161 (51.2) | 411 (57) | 69 (62.7) | |
| CD4 cell count at ART | 0-50 | 630 (36.3) | 1577 (36.7) | 754 (33.2) | 205 (29.4) | 27 (26.0) |
| Initiation (cells/mm3), n (%) | 51-100 | 301 (17.3) | 822 (19.1) | 422 (18.6) | 185 (25.7) | 27 (26.0) |
| 101-200 | 545 (31.4) | 1230 (28.6) | 712 (31.4) | 225 (31.2) | 42 (30.4) | |
| 200-350 | 109 (6.3) | 253 (5.9) | 145 (6.4) | 43 (6.0) | 8 (7.7) | |
| Missing | 153 (8.8) | 420 (9.8) | 235 (10.4) | 63 (8.7) | 6 (5.5) | |
| WHO Stage at ART Initiation, n (%) | I/II | 883 (50.8) | 2225 (51.7) | 1224 (54.0) | 399 (55.3) | 73 (66.4) |
| III | 706 (40.6) | 1706 (39.7) | 863 (38.0) | 258 (35.8) | 29 (26.4) | |
| IV | 149 (8.6) | 371 (8.6) | 181 (8.0) | 64 (8.9) | 8 (7.3) | |
| First-line ART Regimen, n (%) | d4T/3TC/EFV | 1463 (84.2) | 3831 (89.0) | 2093 (92.3) | 675 (93.6) | 107 (97.3) |
| d4T/3TC/NVP | 238 (13.7) | 320 (7.4) | 93 (4.1) | 18 (2.5) | 0 (0.0) | |
| Other | 37 (2.1) | 151 (3.5) | 82 (3.6) | 28 (3.9) | 3 (2.7) | |
| CD4 at ART Initiation (cells/mm3) | Median (IQR) | 74 (23-145.0) | 70 (24-141) | 79 (30-148) | 84.5 (39-144) | 97.5 (47-157.5) |
| Follow-up Time (months) | Median (IQR) | 24.0 (12.9-24.0) 24.0 (14.4-24.0) | 24.0 (13.8-24.0) 24.0 (11.8-24.0) | 24.0 (8.8-24.0) | ||
| Hb at ART Initiation (ug/dl) | Median (IQR) | 11.2 (9.6-12.7) | 11.5 (9.8-12.9) | 11.6 (10.1-13.1) 11.7 (10.2-13.2) | 11.4 (10.3-13.1) | |
| BMI at ART Initiation | Median (IQR) | 20.5 (18.2-23.2) 21.3 (18.9-24.3) | 21.6 (19.3-24.8) 21.5 (18.8-24.7) | 22.2 (19.5-25.8) | ||
| 24-month outcomes | ||||||
| Died | n (%) | 157 (9.0) | 461 (10.7) | 258 (11.4) | 100 (13.8) | 16 (14.5) |
| LTFU | n (%) | 331 (19.0) | 643 (15.0) | 251 (11.1) | 105 (14.6) | 23 (21.0) |
| Transferred out of care | n (%) | 102 (5.9) | 228 (5.3) | 130 (5.7) | 46 (6.4) | 8 (7.3) |
| Alive and in care | n (%) | 1148 (66.1) | 2970 (69.0) | 1629 (71.8) | 470 (65.2) | 63 (57.2) |
ART, antiretroviral therapy; Hb, haemoglobin; LTFU, lost to follow-up; BMI, Body Mass Index